CROS NT appoints Andrew MacGarvey to CEO post
CROS NT has announced the appointment of Andrew MacGarvey as the company’s new CEO and President, starting in 2014.
CROS NT, which is a contract research in the healthcare and biotechnology and biometric spaces, has also announced that Paolo Morelli will move into the role of Chairman, allowing him to dedicate more time to PMH, the holding company which oversees other life science businesses, including ARITHMOS, its technology arm.
“It was a privilege to be asked to take on the role of CEO of CROS NT and I was delighted to accept the position. Paolo has built a company that reflects his philosophy,” MacGarvey said. “Every member of the team is highly valued, as are each and every one of our customers. My job is to continue to build the business, while ensuring we protect the unique way we work, and I am looking forward to the challenge. We are seeing growing demand for our offering, specialist statistical and data services delivered through a global organisation. Following our activities this year we are now able to deliver these services across the pharmaceutical, biotechnology and medical device sectors.”
Reported previously, CROS NT recently acquired U.S.-based Stat-Tech Services, a separate contract research organization focused on biometrics and medical devices. The terms of the deal were not disclosed.